BlueRock Therapeutics announced that its investigational cell therapy, lemiretprocel (OpCT-001), has received Orphan Drug Designations from the U.S. FDA and the EU EMA. US FDA designations are for…

China tests these therapies faster than the rest of the world but regulatory changes could slow them down.

In a phase 1a trial, one-time CRISPR-Cas9 gene editing with CTX310 was associated with no treatment-related dose-limiting toxic effects and with sustained reductions in ANGPTL3 and atherogenic lipi...

Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-related adverse ev |…

QED Science says that its metrics reduce bias by assessing papers solely on the basis of their originality and validity.

Stay updated with the latest news, insights, and analysis from FirstWord PHARMA. FirstWord PHARMA provides comprehensive coverage of key developments and trends.

Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the completion of enrollment for the REPLACE™ Phase…

An AI-generated small-molecule inhibitor treats fibrosis in vivo and in phase I clinical trials.

Dolly’s brush with celebrity could hold lessons for current discussions about reproductive technologies.

/PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration...

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as...

Do we really want to play dice with our planet?